The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

Journal of Autoimmunity

Volumn 111, Issue , 2020, Pages

  Perricone, Carlo ^a   Triggianese, Paola ^b   Bartoloni, Elena ^a   Cafaro, Giacomo ^a   Bonifacio, Angelo F ^a   Bursi, Roberto ^a   Perricone, Roberto ^b   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Autoimmunity; Biologics; Coronavirus; COVID 19; DMARDs; IL 6; Immunosuppressant. IL 1; Infection; Rheumatic; SARS CoV 2; tDMARDs

Indexed keywords

ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; CHLOROQUINE; COLCHICINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; NONSTEROID ANTIINFLAMMATORY AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; CYTOKINE; MONOCLONAL ANTIBODY;

ANTIVIRAL ACTIVITY; CORONAVIRUS DISEASE 2019; DRUG EFFICACY; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; BETACORONAVIRUS; BLOOD; CORONAVIRUS INFECTION; DRUG EFFECT; IMMUNOMODULATION; PANDEMIC; PATHOLOGY; VIRUS PNEUMONIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; BETACORONAVIRUS; CHLOROQUINE; CORONAVIRUS INFECTIONS; CYTOKINES; HUMANS; HYDROXYCHLOROQUINE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083382635     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2020.102468     Document Type: Review

References (307)

1. World Health Organization, Novel coronavirus [cited 2020 Jan 16]. Available from: https://www.who.int/westernpacific/emergencies/novel-coronavirus.
2. Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
3. Remuzzi, A., Remuzzi, G., COVID-19 and Italy: what next?. Lancet, 2020, 10.1016/S0140-6736(20)30627-9 [Online ahead of print].
4. Fang, L., Karakiulakis, G., Roth, M., Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir. Med., 8, 2020, e21.
5. Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q., Liao, J., Yang, H., Hou, W., Zhang, Y., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 395 (2020), 809–815.
6. Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., Richardson, P., COVID-19: combining anti-viral and anti-inflammatory treatments. Lancet Infect. Dis. 20 (2020), 400–402.
7. Lai, C.C., Shih, T.P., Ko, W.C., Tang, H.J., Hsueh, P.R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents, 55, 2020, 1059249.
8. McCloskey, B., Heymann, D.L., SARS to novel coronavirus: old lessons and new lessons. Epidemiol. Infect., 22, 2020, e22.
9. Wilder-Smith, A., Chiew, C.J., Lee, V.J., Can we contain the COVID-19 outbreak with the same measures as for SARS?. Lancet Infect. Dis., 2020, 10.1016/S1473-3099(20)30129-8 [Online ahead of print].
10. Pedersen, F., Ho, Y.C., SARS-CoV-2: a storm is raging. J. Clin. Invest., 2020, 10.1172/JCI137647 [Online ahead of print].
11. Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., et al. Coronavirus infections and immune responses. J. Med. Virol. 92 (2020), 424–432.
12. Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., Liu, D., In vitro anti-viral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 2020, 10.1093/cid/ciaa237.
13. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 (2020), 1054–1062.
14. Xiaoling, X., Mingfeng, H., Tiantian, L., et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. 2003, ChinaXiv, 00026v1.
15. TOCIVID-19, https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19.
16. Sarzi-Puttini, P., Ceribelli, A., Marotto, D., Batticciotto, A., Atzeni, F., Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun. Rev. 18 (2019), 583–592.
17. Smolen, J.S., Landewé, R.B.M., Bijlsma, J.W.J., Burmester, G.R., Dougados, M., Kerschbaumer, A., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis., 2020, 10.1136/annrheumdis-2019-216655 [Online ahead of print].
18. Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., De Boysson, H., Brouwer, E., et al. Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 79:2020 (2018), 19–30.
19. Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J.N., et al. Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78 (2019), 736–745 2019.
20. Ehlers, L., Askling, J., Bijlsma, H.W.J., Cid, M.C., Cutolo, M., Dasgupta, B., et al. EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann. Rheum. Dis. 78 (2018), 1160–1166 2019.
21. Strehl, C., Ehlers, L., Gaber, T., Buttgereit, F., Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front. Immunol., 10, 2019, 1744.
22. Belvisi, M.G., Wicks, S.L., Battram, C.H., Bottoms, S.E.W., Redford, J.E., Woodman, P., et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol. 166 (2001), 1975–1982.
23. Schäcke, H., Schottelius, A., Döcke, W.D., Strehlke, P., Jaroch, S., Schmees, N., et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 227–232.
24. Tullar, C., Issa, F., Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. Transplantation, 103, 2019, 651.
25. Widdifield, J., Bernatsky, S., Paterson, J.M., Gunraj, N., Thorne, J.C., Pope, J., et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 65 (2013), 353–361.
26. Doran, M.F., Crowson, C.S., Pond, G.R., O'Fallon, W.M., Gabriel, S.E., Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46 (2002), 2287–2293.
27. Michaud, K., Wolfe, F., Comorbidities in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21 (2007), 885–906.
28. Dixon, W.G., Suissa, S., Hudson, M., The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res. Ther., 13, 2011, R139.
29. Au, K., Reed, G., Curtis, J.R., Kremer, J.M., Greenberg, J.D., Strand, V., et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70 (2011), 785–791.
30. Listing, J., Gerhold, K., Zink, A., The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52 (2013), 53–61.
31. Accortt, N.A., Lesperance, T., Liu, M., Rebello, S., Trivedi, M., Li, Y., et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res. 70 (2018), 679–684.
32. Franklin, J., Lunt, M., Bunn, D., Symmons, D., Silman, A., Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann. Rheum. Dis. 66 (2007), 308–312.
33. Smalls, D.J., Kiger, R.E., Norris, L.A.B., Bennett, C.L., Love, B.L., Hepatitis B virus reactivation: risk factors and current management strategies. Pharmacotherapy 39 (2019), 1190–1203.
34. Confalonieri, M., Urbino, R., Potena, A., Piattella, M., Parigi, P., Puccio, G., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med. 171 (2005), 242–248.
35. Keh, D., Boehnke, T., Weber-Cartens, S., Schulz, C., Ahlers, O., Bercker, S., et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med. 167 (2003), 512–520.
36. Lamontagne, F., Rochwerg, B., Lytvyn, L., Guyatt, G.H., Møller, M.H., Annane, D., et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ 362 (2018), 1–15.
37. Homma, T., Fukuda, Y., Uchida, Y., Uno, T., Jinno, M., Kishino, Y., et al. Inhibition of virus-induced cytokine production from airway epithelial cells by the late addition of budesonide. Medicina (Kaunas), 56, 2020.
38. Who, W., WHO-2019-nCoV-clinical-2020.4-eng. 2020, 1–21.
39. Clinical, W.H.O., Who, W., WHO-nCoV-Clinical-2020.3-eng. 2020, 1–10.
40. Moreno, G., Rodríguez, A., Reyes, L.F., Gomez, J., Sole-Violan, J., Díaz, E., et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 44 (2018), 1470–1482.
41. Sarda, C., Palma, P., Rello, J., Severe influenza: overview in critically ill patients. Curr. Opin. Crit. Care 25 (2019), 449–457.
42. Hui, D.S.C., Ng, S.S.S., Recommended hospital preparations for future cases and outbreaks of novel influenza viruses. Expet Rev. Respir. Med. 14 (2020), 41–50.
43. Delaney, J.W., Pinto, R., Long, J., Lamontagne, F., Adhikari, N.K., Kumar, A., et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit. Care 20 (2016), 1–11.
44. Cao, B., Gao, H., Zhou, B., Deng, X., Hu, C., Deng, C., et al. Adjuvant corticosteroid treatment in adults with influenza a (H7N9) viral pneumonia. Crit. Care Med. 44 (2016), e318–328.
45. Ni, Y.N., Chen, G., Sun, J., Liang, B.M., Liang, Z.A., The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit. Care 23 (2019), 1–9.
46. Lansbury, L.E., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., Shen Lim, W., Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit. Care Med. 48 (2020), e98–106.
47. Alfaraj, S.H., Al-Tawfiq, J.A., Assiri, A.Y., Alzahrani, N.A., Alanazi, A.A., Memish, Z.A., Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: a cohort study. Trav. Med. Infect. Dis. 29 (2019), 48–50.
48. Chow, E.J., Doyle, J.D., Uyeki, T.M., Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit. Care 23 (2019), 1–11.
49. Li, H., Yang, S.G., Gu, L., Zhang, Y., Yan, X.X., Liang, Z.A., et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other. Resp. Viruses 11 (2017), 345–354.
50. Arabi, Y.M., Mandourah, Y., Al-Hameed, F., Sindi, A.A., Almekhlafi, G.A., Hussein, M.A., et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am. J. Respir. Crit. Care Med. 197 (2018), 757–767.
51. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. PLoS Med. 3 (2006), 1525–1531.
52. Russell, C.D., Millar, J.E., Baillie, J.K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (2020), 473–475.
53. Zumla, A., Hui, D.S., Perlman, S., Middle East respiratory syndrome. Lancet 386 (2015), 995–1007.
54. Lewis, S.R., Pritchard, M.W., Thomas, C.M., Smith, A.F., Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst. Rev., 23, 2019, 7.
55. Shang, L., Zhao, J., Hu, Y., Du, R., Cao, B., On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395 (2020), 683–684.
56. Zhao, J.P., Hu, Y., Du, R.H., Chen, Z., Jin, Y., Zhou, M., Zhang, J., Qu, J., Cao, B., Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia (in Chinese). Zhonghua Jiehe He Huxi Zazhi, 43, 2020, E007.
57. Catella-Lawson, F., Reilly, M.P., Kapoor, S.C., Cucchiara, A.J., DeMarco, S., Tournier, B., Vyas, S.N., FitzGerald, G.A., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 (2001), 1809–1817.
58. Chuang, F.K., Huang, S.M., Liao, C.L., Lee, A.R., Lien, S.P., Chiu, Y.L., Chang, T.H., Tsai, P.L., Lin, R.J., Shih, C.C., Tsai, Y.J., Lin, G.J., Yen, L.C., Anti-inflammatory compound shows therapeutic safety and efficacy against flavivirus infection. Antimicrob. Agents Chemother., 64, 2019.
59. Li, C., Li, C., Zhang, A.J., To, K.K., Lee, A.C., Zhu, H., Wu, H.W., Chan, J.F., Chen, H., Hung, I.F., Li, L., Yuen, K.Y., Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor. PloS One, 9, 2014, e107966.
60. Paul, A.G., Chandran, B., Sharma-Walia, N., Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. Transl. Res. 162 (2013), 77–92.
61. Liu, M., Yang, Y., Gu, C., Yue, Y., Wu, K.K., Wu, J., Zhu, Y., Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. Faseb. J. 21 (2007), 1586–1596.
62. Qiao, W., Wang, C., Chen, B., Zhang, F., Liu, Y., Lu, Q., et al. Ibuprofen attenuates cardiac fibrosis in Streptozotocin-induced diabetic rats. Cardiology 131 (2015), 97–106.
63. Dilly, S., Fotso Fotso, A., Lejal, N., Zedda, G., Chebbo, M., Rahman, F., Companys, S., Bertrand, H.C., Vidic, J., Noiray, M., Alessi, M.C., Tarus, B., Quideau, S., Riteau, B., Slama-Schwok, A., From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J. Med. Chem. 61 (2018), 7202–7217.
64. Mazzetti, A., Neary, J.D., Outcome switching in triple therapy in influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest 154 (2018), 998–999.
65. ClinicalTrialsgov Identifier: NCT04325633.
66. Day, M., Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ, 368, 2020, 1086.
67. Moore, N., Coronary risks associated with diclofenac and other NSAIDs: an update. Drug Saf. 43 (2020), 301–318.
68. Wen, Y.C., Hsiao, F.Y., Lin, Z.F., Fang, C.C., Shen, L.J., Risk of stroke associated with use of nonsteroidal anti-inflammatory drugs during acute respiratory infection episode. Pharmacoepidemiol. Drug Saf. 27 (2018), 645–651.
69. Wen, Y.C., Hsiao, F.Y., Chan, K.A., Lin, Z.F., Shen, L.J., Fang, C.C., Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study. J. Infect. Dis. 215 (2017), 503–509.
70. Little, P., Moore, M., Kelly, J., et al. PIPS Investigators. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ, 347, 2013 347 f6041.
71. Little, P., Stuart, B., Andreou, P., et al. Primary care randomised controlled trial of a tailored interactive website for the self-management of respiratory infections (internet doctor). BMJ Open, 6, 2016, e009769.
72. Little, P., Non-steroidal anti-inflammatory drugs and covid-19. BMJ, 368, 2020, m1185.
73. Day, M., Covid-19: European drugs agency to review safety of ibuprofen. BMJ, 368, 2020, m1168.
74. Shukla, A.M., Wagle Shukla, A., Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context, 8, 2019.
75. Adelusi, S.A., Salako, L.A., Kinetics of the distribution and elimination of chloroquine in the rat. Gen. Pharmacol. 13 (1982), 433–437.
76. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., Cauda, R., Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect. Dis. 3 (2003), 722–727.
77. Al-Bari, M.A.A., Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol. Res. Perspect., 5, 2017, e00293.
78. Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., Raoult, D., Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob. Agents, 2020, 105932.
79. Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., Van Ranst, M., In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 323 (2004), 264–268.
80. Vincent, M.J., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2, 2005, 69.
81. Kono, M., et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Anti-viral Res. 77 (2008), 150–152.
82. Wang, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30 (2020), 269–271.
83. Sarma, P, Kaur, H, Kumar, H, et al. Virological and clinical cure in Covid-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J. Med. Virol., 2020, 10.1002/jmv.25898.
84. Keyaerts, E., et al. Anti-viral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob. Agents Chemother. 53 (2009), 3416–3421.
85. Takano, T., Katoh, Y., Doki, T., Hohdatsu, T., Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo. Anti-viral Res. 99 (2013), 100–107.
86. Barnard, D.L., et al. Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 17 (2006), 275–284.
87. Gao, J., Tian, Z., Yang, X., Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 14 (2020), 72–73.
88. Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi ChinJ Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Tuberc. Respir. Dis. 43 (2020), 185–188.
89. Touret, F., de Lamballerie, X., Of chloroquine and COVID-19. Anti-viral Res., 177, 2020, 104762.
90. Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., Einav, S., A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care, 2020, 10.1016/j.jcrc.2020.03.005.
91. Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Medded, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., Dupont, H.T., Honore, S., Colson, P., Chabriere, E., La Scola, B., Rolain, J.M., Brouqui, P., Raoult, D. Sr., Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020, 10.1016/j.ijantimicag.2020.105949.
92. Melles, R.B., Marmor, M.F., The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132 (2014), 1453–1460.
93. SIMIT Società Italiana di Malattie Infettive e Tropicali SEZIONE REGIONE LOMBARDIA. Vademecum per la cura delle persone con malattia da COVID-19 - versione 2.0 2020.
94. Skorpen, C.G., et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75 (2016), 795–810.
95. D'Antiga, A., Coronaviruses and Immunosuppressed Patients. The Facts during the Third Epidemic. Liver Transplant., 2020, 10.1002/lt.25756.
96. He, D., Zhang, C., Zhao, X., Zhang, Y., Dai, Q., Li, Y., Chu, L., Teriflunomide for multiple sclerosis Summary of findings for the main comparison. Cochrane Database Syst. Rev., 3, 2016, CD009882.
97. Xu, X., Williams, J., Bremer, E., Finnegan, A., Chong, A., Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270 (1995), 12398–12403.
98. Williamson, R., Yea, C., Robson, P., Curnock, A., Gadher, S., Hambleton, A., Woodward, K., Bruneau, J., Hambleton, P., Moss, D., Thomson, T., Spinella-Jaegle, S., Morand, P., Courtin, O., Saute's, C., Westwood, R., Hercend, T., Kuo, E., Ruuth, E., Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270 (1995), 22467–22472.
99. Munier-Lehmann, H., Vidalain, P.O., Tangy, F., Janin, Y.L., On dihydroorotate dehydrogenases and their inhibitors and uses. J. Med. Chem. 56 (2013), 3148–3167.
100. Kotton, C., Kumar, D., Caliendo, A., Åsberg, A., Chou, S., Snydman, D., Allen, U., Humar, A., International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89 (2010), 779–795.
101. Eid, A., Arthurs, S., Deziel, P., Wilhelm, M., Razonable, R., Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin. Transplant. 22 (2008), 162–170.
102. Silva, J., Pérez-González, V., Lopez-Medrano, F., Alonso-Moralejo, R., Fernández-Ruiz, M., San-Juan, R., Brañas, P., Folguera, M., Aguado, J., De Pablo-Gafas, A., Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: a case series and review of the literature. Clin. Transplant. 32 (2018), 1–7.
103. Rifkin, L., Minkus, C., Pursell, K., Jumroendararasame, C., Goldstein, D., Utility of leflunomide in the treatment of drug resistant cytomegalovirus retinitis. Ocul. Immunol. Inflamm. 25 (2017), 93–96.
104. Dunn, J., Weinberg, A., Chan, L., Mandava, N., Levi, M., Olson, J., Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. JAMA Ophthalmology 131 (2013), 958–960.
105. El Chaer, F., Mori, N., Shah, D., Oliver, N., Wang, E., Jan, A., Doan, V., Tverdek, F., Tayar, J., Ariza-Heredia, E., Chemaly, R., Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: a case series. Antivir. Res. 135 (2016), 91–96.
106. Henao-Martínez, A., Weinberg, A., Waldman, W., Levi, M., Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man. J. Clin. Virol. 54 (2012), 276–278.
107. Waldman, W., Knight, D., Blinder, L., Shen, J., Lurain, N., Miller, D., Sedmak, D., Williams, J., Chong, A., Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 42 (1999), 412–418.
108. Knight, D., Hejmanowski, A., Dierksheide, J., Williams, J., Chong, A., Waldman, W., Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplant 71 (2001), 170–174.
109. Tatarowicz, W., Lurain, N., Thompson, K., A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J. Infect. Dis. 166 (1992), 904–907.
110. Chacko, B., John, G., Leflunomide for cytomegalovirus: bench to bedside. Transpl. Infect. Dis. 14 (2012), 111–120.
111. Qi, R., Hua-Song, Z., Xiao-Feng, Z., Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. Eur. J. Med. Res., 18, 2013, 3.
112. Bilger, A., Plowshay, J., Ma, S., Nawandar, D., Barlow, E., Romero-Masters, J., Bristol, J., Li, Z., Tsai, M., Delecluse, H., Kenney, S., Leflunomide/teriflunomide inhibit Epstein-barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication. Oncotarget 8 (2017), 44266–44280.
113. Zhou, X., Kubo, M., Nishitsuji, H., Kurihara, K., Ikeda, T., Ohashi, T., Azuma, M., Masuda, T., Kannagi, M., Inducible-costimulator-mediated suppression of human immunodeficiency virus type 1 replication in CD4+ T lymphocytes. Virology 325 (2004), 252–263.
114. Sepúlveda, C., García, C., Damonte, E., Antiviral activity of A771726, the active metabolite of leflunomide, against Junín virus. J. Med. Virol. 90 (2018), 819–827.
115. Mei-jiao, G., Shi-fang, L., Yan-yan, C., Jun-jun, S., Yue-feng, S., Ting-ting, R., Yong-Guang, Z., Hui-Yun, C., Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. Biomed. Pharmacother. 118 (2019), 1–7.
116. Martin, S., Chiramel, A., Schmidt, M., Chen, Y., Whitt, N., Watt, A., Dunham, M.E., Shifflett, K., Traeger, S., Leske, A., Buehler, E., Martellaro, C., Brandt, J., Wendt, L., Groseth, A., Feldmann, H., Hoenen, T., A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. Genome Med. 10 (2018), 1–14.
117. Cuellar-Rodriguez, J., Stephany, B., Poggio, E., Mossad, S., Goldfarb, D., Lard, M., Askar, M., Farica, R., Srinivas, T., Braun, W., Shoskes, D., Flecher, S., Schmitt, S., Shrestha, R., Avery, R., Contrasting patterns of viral load response in transplant recipients with BK polyomavirus DNAemia on leflunomide therapy. Clin. Transplant. 27 (2013), 230–237.
118. Wu, M., Chen, Y., Hung, L., Lee, C., Chen, H., Hsu, Y., Wu, M., Successful treatment for BK virus nephropathy by leflunomide in a kidney transplant patient: a case report. Transplant. Proc. 51 (2019), 1472–1474.
119. Faguer, S., Hirsch, H., Kamar, N., Guilbeau-Frugier, C., Ribes, D., Guitard, J., Esposito, L., Cointault, O., Modesto, A., Lavit, M., Mengelle, C., Rostaing, L., Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl. Int. 20 (2007), 962–969.
120. Hirsch, H., Randhawa, P., BK polyomavirus in solid organ transplantation—guidelines from the American society of transplantation infectious diseases community of practice. Clin. Transplant. 33 (2019), 1–19.
121. Johnston, O., Jaswal, D., Gill, J., Doucette, S., Fergusson, A., Knoll, G., Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplant 89 (2010), 1057–1070.
122. Wu, W., Ho, L., Chen, P., Tsai, Y., Hsu, S., Chang, D., Lai, J., Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells. J. Clin. Immunol. 31 (2011), 1065–1078.
123. Khong, W., Foo, D., Trasti, S., Tan, E., Alonso, S., Sustained high levels of interleukin-6 contribute to the pathogenesis of Enterovirus 71 in a neonate mouse model. J. Virol. 85 (2011), 3067–3076.
124. Lin, T., Hsia, S., Huang, Y., Wu, C., Chang, L., Proinflammatory cytokine reactions in Enterovirus 71 infections of the central nervous system. Clin. Infect. Dis. 36 (2003), 269–274.
125. Hung, H., Shih, S., Chang, T., Fang, M., Hsu, J., The combination effects of LiCL and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication. PloS One, 9, 2014, e111331.
126. Chong, A., Zeng, H., Knight, D., Shen, J., Meister, G., Williams, J., Waldman, W., Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am. J. Transplant. 6 (2006), 69–75.
127. Dunn, M., Knight, D., Waldman, W., Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir. Ther. 16 (2011), 309–317.
128. Sanders, S., Harisdangkul, V., Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci. 323 (2002), 190–193.
129. Pinschewer, D., Ochsenbein, A., Fehr, T., Zinkernagel, R., Leflunomide-mediated suppression of antiviral antibody and T cell responses: differential restoration by uridine. Transplant 72 (2001), 712–719.
130. Dasgupta, A., Therapeutic drug monitoring of mycophenolic acid. Adv. Clin. Chem. 76 (2016), 165–184.
131. Leyssen, P., Balzarini, J., De Clercq, E., Neyts, J., The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against Flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79 (2005), 1943–1947.
132. Cho, J., Yi, H., Jang, E., Lee, M., Lee, J., Kang, C., Lee, C., Kim, K., Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. Biochem. Biophys. Res. Commun. 494 (2017), 298–304.
133. To, K., Mok, K., Chan, A., Cheung, N., Wang, P., Lui, Y., Chan, J., Chen, H., Chan, K., Kao, R., Yuen, K., Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. J. Gen. Virol. 97 (2016), 1807–1817.
134. Park, J., Ávila-Pérez, G., Nogales, A., Blanco-Lobo, P., de la Torre, J.C., Martínez-Sobrido, L., Identification and characterization of novel compounds with broad spectrum antiviral activity against influenza A and B viruses. J. Virol., 94, 2020.
135. Adcock, R., Chu, Y., Golden, J., Chung, D., Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay. Antivir. Res. 138 (2017), 47–56.
136. Goebel, S., Snyder, B., Sellati, T., Saeed, M., Ptak, R., Murray, M., Bostwickb, R., Raynerc, J., Koidea, F., Kalkeri, R., A sensitive virus yield assay for evaluation of Antivirals against Zika Virus. J. Virol. Met. 238 (2016), 13–20.
137. Morrey, J., Smee, D., Sidwell, R., Tseng, C., Identification of active antiviral compounds against a New York isolate of West Nile virus. Antivir. Res. 55 (2002), 107–116.
138. Sebastian, L., Madhusudana, S., Ravi, V., Desai, A., Mycophenolic acid inhibits replication of Japanese encephalitis virus. Chemotherapy 57 (2011), 56–61.
139. Takhampunya, R., Ubol, S., Houng, H., Cameron, C., Padmanabhan, R., Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87 (2006), 1947–1952.
140. Leyssen, P., Van Lommel, A., Drosten, C., Schmitz, H., De Clercq, E., Neyts, J., A novel model for the study of the therapy of flavivirus infections using the Modoc virus. Virology 279 (2001), 27–37.
141. Charlier, N., Leyssen, P., Paeshuyse, J., Drosten, C., Schmitz, H., Van Lommel, A., De Clercq, E., Neyts, J., Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J. Gen. Virol. 83 (2002), 1887–1896.
142. Khan, M., Dhanwani, R., Patro, I.K., Rao, P.V.L., Parida, M., Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antivir. Res. 89 (2011), 1–8.
143. Smee, D., Hurst, B., Evans, W., Clyde, N., Wright, S., Jung, K., Peterson, C., Day, C., Viruses that exhibit different cytopathogenic properties. J. Virol. Met. 246 (2018), 51–57.
144. Mei-jiao, G., Shi-fang, L., Yan-yan, C., Jun-jun, S., Yue-feng, S., Ting-ting, R., Guang, Y., Zhang, Yun H., Chang. Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. Biomed. Pharmacother. 118 (2019), 1–7.
145. Chang, Q., Guo, F., Li, X., Zhou, J., Cai, X., Pan, Q., Ma, X., The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection. Vet. Res. Commun. 42 (2018), 309–313.
146. Sepúlveda, C., García, C., Fascio, M., D'Accorso, N., Docampo Palacios, M., Pellón, R., Damonte, E., Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antivir. Res. 93 (2012), 16–22.
147. Dang, W., Yin, Y., Wang, Y., Wang, W., Su, J., Sprengers, D., Van der Laan, L., Felczak, K., Pankiewicz, K., Chang, K., Koopmans, M., Metselaar, H., Peppelenbosch, M., Pan, Q., Inhibition of calcineurin or IMP dehydrogenase exerts moderate to potent antiviral activity against norovirus replication. Antimicrob. Agents Chemother. 61 (2017), 1–17.
148. Ölschläger, S., Neyts, J., Günther, S., Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antivir. Res. 91 (2011), 89–93.
149. Robertson, C., Hermann, L., Coombs, K., Mycophenolic acid inhibits avian reovirus replication. Antivir. Res. 64 (2004), 55–61.
150. Hermann, L., Coombs, K., Mycophenolic acid inhibits replication of Type 2 Winnipeg, a cerebrospinal fluid-derived reovirus isolate. Can. J. Infect Dis. 15 (2004), 261–265.
151. Livonesi, M., Moro De Sousa, R., Moraes Figueiredo, L., In vitro study of antiviral activity of mycophenolic acid on Brazilian orthobunyaviruses. Intervirology 50 (2007), 204–208.
152. Marroquí, L., Estepa, A., Perez, L., Inhibitory effect of mycophenolic acid on the replication of infectious pancreatic necrosis virus and viral hemorrhagic septicemia virus. Antivir. Res. 80 (2008), 332–338.
153. Yin, Y., Wang, Y., Dang, W., Xu, L., Su, J., Zhou, X., Wang, W., Felczak, K., Van der Laan, L., Pankiewicz, K., Van der Eijk, A., Bijvelds, M., Sprengers, D., De Jonge, H., Koopmans, M., Metselaar, H., Peppelenbosch, M., Pan, Q., Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antivir. Res. 133 (2016), 41–49.
154. Diamond, M., Zachariah, M., Harris, E., Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304 (2002), 211–221.
155. Takhampunya, R., Ubol, S., Houng, H., Cameron, C., Padmanabhan, R., Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87 (2006), 1947–1952.
156. Uematsu, J., Sakai-Sugino, K., Kihira-Nakanishi, S., Yamamoto, H., Hirai, K., Kawano, M., Nishio, M., Tsurudome, M., O'Brien, M., Komada, H., Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine. Drug Discov. Theroy 13 (2019), 314–321.
157. Pan, Q., De Ruiter, P., Metselaar, H., Kwekkeboom, J., De Jonge, J., Tilanus, H., Janssen, H., Van der Laan, L., Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology 55 (2012), 1673–1683.
158. Fang, S., Su, J., Liang, B., Li, X., Li, Y., Jiang, J., Huang, J., Zhou, B., Ning, C., Li, J., Ho, W., L Y, Chen, H., Liang, H., Ye, L., Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Sci. Rep. 7 (2017), 1–12.
159. Chan, J., Lau, S., To, K., Cheng, V., Woo, P., Yue, K., Middle East Respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28 (2015), 465–522.
160. Al Ghamdi, M., Alghamdi, K., Ghandoora, Y., Alzahrani, A., Salah, F., Alsulami, A., Bawayan, M., Vaidya, D., Perl, T., Sood, G., Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the kingdom of Saudi Arabia. BMC Infect. Dis. 16 (2016), 1–7.
161. Lin, M., Moses, D., Hsieh, C., Cheng, S., Chen, Y., Sun, C., Chen, Y., Sun, C., Chou, C., Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antivir. Res. 150 (2018), 155–163.
162. Chan, J., Chan, K., Kao, R., To, K., Zheng, B., Li, C., Li, P., Dai, J., Mok, F., Chen, H., Hayden, F., Yuen, K., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67 (2013), 606–616.
163. Chan, J., Yao, Y., Yeung, M., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K., Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 (2015), 1904–1913.
164. Barnard, D., Day, C., Bailey, K., Heiner, M., Montgomery, R., Lauridsen, L., Winslowa, S., Hoopesb, J., Li, J., Lee, J., Carson, D., Cottam, H., Sidwell, R., Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antivir. Res. 71 (2006), 53–63.
165. Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., Doerr, H.W., Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003), 2045–2046.
166. Neyts, J., Andrei, G., De Clercq, E., The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42 (1998), 216–222.
167. Ying, C., Colonno, R., De Clercq, E., Neyts, J., Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. Antivir. Res. 73 (2007), 192–196.
168. Ying, C., De Clercq, E., Neyts, J., Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. Antivir. Res. 48 (2000), 117–124.
169. Planterose, D., Antiviral and cytotoxic effects of mycophenolic acid. J. Gen. Virol. 4 (1969), 629–630.
170. Reis, A., Reinhard, T., Voiculescu, A., Mayer, K., Sundmacher, R., Hochaktive antivirale und immunsuppressive kombinationstherapie mit acyclovir und mycophenolatmofetil nach keratoplastik bei herpetischer grunderkrankung. Klin Monbl Augenheilkd 218 (2001), 183–186.
171. Margolis, D., Heredia, A., Gaywee, J., Oldach, D., Drusano, G., Redfield, R., Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrigenase, have profound and synergistic anti-HIV acrivity. J. Acquir. Immune Defic. Syndr. 21 (1999), 362–370.
172. Hossain, M., Coull, J., Drusano, G., Margolis, D., Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antivir. Res. 55 (2002), 41–52.
173. Margolis, D., Knew, S., Coull, J., Ylisastigui, L., Turner, D., Wise, H., Hossain, M., Lanier, E., Shaw, L., Back, D., The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyhanosine triphosphate and a decrease in plasma HIV-1 RNA. J. Acquir. Immune Defic. Syndr. 31 (2002), 45–49.
174. Borroto-Esoda, K., Myrick, F., Feng, J., Jeffrey, J., Furman, P., In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48 (2004), 4387–4394.
175. Sankatsing, S., Jurriaans, S., Van Swieten, P., Van Leth, F., Cornelissen, M., Miedema, F., Lange, J., Schuitemaker, H., Prins, J., Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 18 (2004), 1925–1931.
176. Sebastian, L., Desai, A., Yogeeswari, P., Sriram, D., Madhusudana, S.N., Ravi, V., Combination of N-methylisatin-β-thiosemicarbazone derivative (SCH16) with ribavirin and mycophenolic acid potentiates the antiviral activity of SCH16 against Japanese encephalitis virus in vitro. Lett. Appl. Microbiol. 55 (2012), 234–239.
177. Scharpé, J., Evenepoel, P., Maes, B., Bammens, B., Claes, K., Osterhaus, A., Vanrenterghem, Y., Peetermans, E., Influenza vaccination is efficacious and safe in renal transplant recipients. Am. J. Transplant. 8:2 (2008), 332–337.
178. Inui, Y., Yakushijin, K., Okamura, A., Tanaka, Y., Shinzato, I., Nomura, T., Ichikawa, H., Mizutami, Y., Kitao, A., Kurata, K., Kakiuchi, S., Miyata, Y., Sanada, Y., Kitagawa, K., Uryu, K., Kawamoto, S., Yamamoto, K., Matsuoka, H., Murayama, T., Ito, M., Minami, H., Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 21 (2019), 1–8.
179. Kim, W., Kim, S., Oh, J., Jeong, Y., Rhu, J., Kim, K., Lee, J., Choi, G., Kim, J., Joh, J., Incidence and risk factors for herpes zoster after adult liver transplantation. Ann. Surg. Treat. Res. 96 (2019), 95–99.
180. Monlezun, D., John, M., Dortonne, I., Gaines, I., Carsky, K., Chernobylsky, D., Ferrin, B., Paramesh, A., Zhang, R., McDermott, C., Parker, G., Darden, M., Buell, J., Postrenal transplant infection: what is the effect of specific immunosuppressant agents?. Surgery 164 (2018), 895–899.
181. Holmes, M., Caplin, B., Atkinson, C., Smith, C., Harber, M., Sweny, P., Haque, T., Prospective monitoring of epstein-barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. Transplantation 87 (2009), 852–856.
182. Brown, P.M., Pratt, A.G., Isaacs, J.D., Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat. Rev. Rheumatol. 12 (2016), 731–742.
183. Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M.C., Ralandison, S., Gasque, P., Methotrexate an old drug with new tricks. Int. J. Mol. Sci., 20(20), 2019.
184. Beck, S., Zhu, Z., Oliveira, M.F., Smith, D.M., Rich, J.N., Bernatchez, J.A., Siqueira-Neto, J.L., Mechanism of action of methotrexate against Zika virus. Viruses, 11, 2019, 4.
185. Marks, M., Marks, J.L., Viral arthritis. Clin. Med. 16 (2016), 129–134.
186. Amaral, J.K., Sutaria, R., Schoen, R.T., Treatment of chronic Chikungunya arthritis with methotrexate: a systematic review. Arthritis Care Res. 70 (2018), 1501–1508.
187. Fukuda, W., Hanyu, T., Katayama, M., Mizuki, S., Okada, A., Miyata, M., Handa, Y., Hayashi, M., Koyama, Y., Arii, K., Kitaori, T., Hagiyama, H., Urushidani, Y., Yamasaki, T., Ikeno, Y., Suzuki, T., Omoto, A., Sugitani, T., Morita, S., Inokuma, S., Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann. Rheum. Dis. 76 (2017), 1051–1056.
188. Mashima, A., Usui, Y., Umazume, K., Muramatsu, D., Goto, H., Successful treatment of necrotizing retinitis with Epstein-Barr virus-positive ocular fluid by intravitreal methotrexate injection. Ocul. Immunol. Inflamm. 3 (2019), 1–4, 10.1080/09273948.2019.1609047.
189. Slobodnick, A., Shah, B., Krasnokutsky, S., Pillinger, M.H., Update on colchicine. Rheumatology 57:2018 (2017), i4–i11.
190. Tardif, J.C., Kouz, S., Waters, D.D., Bertrand, O.F., Diaz, R., Maggioni, A.P., Pinto, F.J., Ibrahim, R., Gamra, H., Kiwan, G.S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J.C., Lavoie, M.A., Dubé, M.P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L'Allier, P.L., Guertin, M.C., Roubille, F., Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381 (2019), 2497–2505.
191. Perico, N., Ostermann, D., Bontempeill, M., et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen- 1 expression on human T lymphocytes and inhibits T cell activation. J. Am. Soc. Nephrol. 7 (1996), 594–601.
192. Pope, R.M., Tschopp, J., The role of interleukin- 1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 56 (2007), 3183–3188.
193. Imazio, M., Bobbio, M., Cecchi, E., et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 112 (2005), 2012–2016.
194. Cerquaglia, C., Diaco, M., Nucera, G., La Regina, M., Montalto, M., Manna, R., Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr. Drug Targets - Inflamm. Allergy 4 (2005), 117–124.
195. Cacoub, P.P., Colchicine for treatment of acute or recurrent pericarditis. Lancet 383 (2014), 2193–2194.
196. Ravelli, R.B., Gigant, B., Curmi, P.A., et al. Insight into tubulin regulation from a complex with colchicine and a stathminlike domain. Nature 428 (2004), 198–202.
197. Fordham, J.N., Kirwan, J., Cason, J., Currey, H.L., Prolonged reduction in polymorphonucler adhesion following oral colchicine. Ann. Rheum. Dis. 40 (1981), 605–608.
198. Misawa, T., Takahama, M., Kozaki, T., et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14 (2013), 454–460.
199. Tong, D.C., Wilson, A.M., Layland, J., Colchicine in Cardiovascular Disease: an Ancient Drug with Modern Tricks, 102 Heart, 2016, 995–1002.
200. Papageorgiou, N., Briasoulis, A., Lazaros, G., et al. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc. Theroy 35 (2017), 10–18.
201. Apostolidou, E., Skendros, P., Kambas, K., et al. Neutrophil extracellular traps regulate IL-1(-mediated inflammation in familial Mediterranean fever. Ann. Rheum. Dis. 75 (2016), 269–277.
202. Martínez, G.J., Robertson, S., Barraclough, J., et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc., 4, 2015, e002128.
203. Robertson, S., Martinez, G.J., Payet, C.A., et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin. Sci. (Lond.) 130 (2016), 1237–1246.
204. Nidorf, S.M., Verma, S., Is there a role for colchicine in acute coronary syndromes?. J. Am. Heart Assoc., 4, 2015, e002372.
205. Sun, A., Wang, Y.P., Chia, J.S., Liu, B.Y., Chiang, C.P., Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease. J. Oral Pathol. Med. 38 (2009), 401–405.
206. Richter, M., Boldescu, V., Graf, D., Streicher, F., Dimoglo, A., Bartenschlager, R., Klein, C.D., Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-activated prodrugs as anti-viral agents. ChemMedChem 14 (2019), 469–483.
207. Biswas, K., Das Sarma, J., Effect of microtubule disruption on neuronal spread and replication of demyelinating and nondemyelinating strains of mouse hepatitis virus in vitro. J. Virol. 88 (2014), 3043–3079.
208. Lu, N., Yang, Y., Liu, H., Ding, X., Ou, Y., Xia, J., Du, Y., Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine. Biotechnology, 9, 2019, 392.
209. Worachartcheewan, A., Songtawee, N., Siriwong, S., Prachayasittikul, S., Nantasenamat, C., Prachayasittikul, V., Rational design of colchicine derivatives as anti-HIV agents via QSAR and molecular docking. Med. Chem. 15 (2019), 328–340.
210. Angelini, M.M., Akhlaghpour, M., Neuman, B.W., Buchmeier, M.J., Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio, 4, 2013, e00524-13 pii.
211. Chen, I.Y., Moriyama, M., Chang, M.F., Ichinohe, T., Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front. Microbiol., 10, 2019, 50.
212. Conti, P., Ronconi, G., Caraffa, A., Gallenga, C.E., Ross, R., Frydas, I., Kritas, S.K., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents, 34, 2020, 10.23812/CONTI-E.
213. Channappanavar, R., Perlman, S., Evaluation of activation and inflammatory activity of myeloid cells during pathogenic human coronavirus infection. Methods Mol. Biol. 2099 (2020), 195–204.
214. Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., Tian, D.S., Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis., 2020, 10.1093/cid/ciaa248.
215. Gandolfini, I., Delsante, M., Fiaccadori, E., Zaza, G., Manenti, L., Degli Antoni, A., Peruzzi, L., Riella, L.V., Cravedi, P., Maggiore, U., COVID-19 in kidney transplant recipients. Am. J. Transplant., 2020, 10.1111/ajt.15891.
216. Apte, R.N., Voronov, E., Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. J. Leukoc. Biol. 102 (2017), 293–306.
217. Awasthi, S., Yadav, K.K., Pandey, M., Mahdi, A.A., Awasthi, N., Pediatr. Pulmonol. 53 (2018), 1276–1283.
218. Sichelstiel, A., Yadava, K., Trompette, A., Salami, O., Iwakura, Y., Nicod, L.P., Marsland, B.J., Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation. PloS One, 9, 2014, e98440.
219. Wolf, S., Taylor, A., Zaid, A., Freitas, J., Herrero, L.J., Rao, S., Suhrbier, A., Forwood, M.R., Bucala, R., Mahalingam, S., Inhibition of interleukin-1β signaling by anakinra demonstrates a critical role of bone loss in experimental arthritogenic alphavirus infections. Arthritis Rheum. 71 (2019), 1185–1190.
220. Guo, S., Yang, C., Diao, B., Huang, X., Jin, M., Chen, L., Yan, W., Ning, Q., Zheng, L., Wu, Y., Chen, Y., The NLRP3 inflammasome and IL-1β accelerate immunologically mediated pathology in experimental viral fulminant hepatitis. PLoS Pathog., 11, 2015, e1005155.
221. De Benedetti, F., Gattorno, M., Anton, J., Ben-Chetrit, E., Frenkel, J., Hoffman, H.M., Koné-Paut, I., et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N. Engl. J. Med. 378 (2018), 1908–1919.
222. Arend, W.P., Malyak, M., Guthridge, C.J., Gabay, C., Interleukin‐1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16 (1998), 27–55.
223. Dubois, E.A., Rissmann, R., Cohen, A.F., Rilonacept and canakinumab. Br. J. Clin. Pharmacol. 71 (2011), 639–641.
224. Ridker, P.M., MacFadyen, J.G., Thuren, T., Everett, B.M., Libby, P., Glynn, R.J., CANTOS Trial Group. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390 (2017), 1833–1842.
225. He, L., Ding, Y., Zhang, Q., Che, X., He, Y., Shen, H., Wang, H., Li, Z., Zhao, L., Geng, J., Deng, Y., Yang, L., Li, J., Cai, J., Qiu, L., Wen, K., Xu, X., Jiang, S., Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210 (2006), 288–297.
226. Davignon, J.L., Rauwel, B., Degboé, Y., Constantin, A., Boyer, J.F., Kruglov, A., Cantagrel, A., Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review. Arthritis Res. Ther., 20, 2018, 229.
227. Li, P., Zheng, Y., Chen, X., Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front. Pharmacol., 8, 2017, 460.
228. Rutherford, A.I., Patarata, E., Subesinghe, S., Hyrich, K.L., Galloway, J.B., Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 57 (2018), 997–1001.
229. Willeaume, V., Kruys, V., Mijatovic, T., Huez, G., Tumor necrosis factor-alpha production induced by viruses and by lipopolysaccharides in macrophages: similarities and differences. J. Inflamm. 46:1 (1995-1996), 1–12.
230. Cui, J., Chen, Y., Wang, H.Y., Wang, R.F., Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum. Vaccines Immunother. 10 (2014), 3270–3285.
231. Wortzman, M.E., Clouthier, D.L., McPherson, A.J., Lin, G.H., Watts, T.H., The contextual role of TNFR family members in CD8(+) T-cell control of viral infections. Immunol. Rev. 255 (2013), 125–148.
232. Huang, J., Yu, S., Ji, C., Li, J., Structural basis of cell apoptosis and necrosis in TNFR signaling. Apoptosis 20:2 (2015), 210–215.
233. Chiu, Y.M., Chen, D.Y., Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expet Rev. Clin. Immunol. 16 (2020), 207–228.
234. Lee, Y.H., Bae, S.C., Song, G.G., Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int. J. Rheum. Dis. 16 (2013), 527–531.
235. Hakim, M.S., Ding, S., Chen, S., Yin, Y., Su, J., van der Woude, C.J., Fuhler, G.M., Peppelenbosch, M.P., Pan, Q., Wang, W., TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway. Virus Res. 253 (2018), 28–37.
236. Kumar, A., Coquard, L., Herbein, G., Targeting TNF-alpha in HIV-1 infection. Curr. Drug Targets 17 (2016), 15–22.
237. Kumar, A., Abbas, W., Herbein, G., The use of TNF inhibitors can have significant impact on HIV disease progression. TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?. Mediat. Inflamm., 2013, 484378 2013.
238. Filippi, J., Roger, P.M., Schneider, S.M., Durant, J., Breittmayer, J.P., Benzaken, S., Bernard, A., Dellamonica, P., Hébuterne, X., Groupe d'Etude Niçois Polyvalent en Infectiologie (GENPI). Infliximab and human immunodeficiency virus infection: viral load reduction and CD4+ T-cell loss related to apoptosis. Arch. Intern. Med. 166 (2006), 1783–1784.
239. Nie, Z., Scott, G.D., Weis, P.D., Itakura, A., Fryer, A.D., Jacoby, D.B., Role of TNF-α in virus-induced airway hyperresponsiveness and neuronal M₂ muscarinic receptor dysfunction. Br. J. Pharmacol. 164 (2011), 444–452.
240. Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., Crackower, M.A., Fukamizu, A., Hui, C.C., Hein, L., Uhlig, S., Slutsky, A.S., Jiang, C., Penninger, J.M., Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:7047 (2005 Jul 7), 112–116.
241. Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K.A., Gerhart, M., Davis, R., Fitzner, J.N., Johnson, R.S., Paxton, R.J., March, C.J., Cerretti, D.P., A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997), 729–733.
242. Haga, S., Nagata, N., Okamura, T., Yamamoto, N., Sata, T., Yamamoto, N., Sasazuki, T., Ishizaka, Y., TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antivir. Res. 85 (2010), 551–555.
243. McDermott, J.E., Mitchell, H.D., Gralinski, L.E., Eisfeld, A.J., Josset, L., Bankhead, A. 3rd, Neumann, G., Tilton, S.C., Schäfer, A., Li, C., Fan, S., McWeeney, S., Baric, R.S., Katze, M.G., Waters, K.M., The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus. BMC Syst. Biol., 23, 2016, 93.
244. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H Yu H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., Ning, Q., Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. 2020 Mar 27, pii, 137244 J. Clin. Invest.
245. Chinese Clinical Trial Registry, Registration number: ChiCTR2000030089.
246. Tanaka, T., Kishimoto, T., The biology and medical implications of interleukin-6. Canc. Immunol. Res. 2 (2014), 288–294.
247. Xu, X.J., Tang, Y.M., Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Canc. Lett. 343 (2014), 172–178.
248. Brudno, J.N., Kochenderfer, J.N., Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127 (2016), 3321–3330.
249. Lee, D.W., Gardner, R., Porter, D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
250. Kotch, C., Barret, D., Theachey, D.T., Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expet Rev. Clin. Immunol. 15 (2019), 813–822.
251. Le, R.Q., Li, L., Yuan, W., et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncol. 23 (2018), 943–947.
252. Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., Du, B., Li, L.J., Zeng, G., Yuen, K.Y., Chen, R.C., Tang, C.L., Wang, T., Chen, P.Y., Xiang, J., Li, S.Y., Wang, J.L., Liang, Z.J., Peng, Y.X., Wei, L., Liu, Y., Hu, Y.H., Peng, P., Wang, J.M., Liu, J.Y., Chen, Z., Li, G., Zheng, Z.J., Qiu, S.Q., Luo, J., Ye, C.J., Zhu, S.Y., Zhong, N.S., China medical treatment expert group for covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, 10.1056/NEJMoa2002032.
253. Chen, L., Liu, H.G., Liu, W., et al. Analysis of Clinical Features of 29 Patients with 2019 Novel Coronavirus Pneumonia. 2020, Zhonghua Jie He He Hu Xi Za Zhi, 10.3760/cma.j.issn.1001-0939.2020.0005 (Articolo in cinese).
254. Wu, D., Wu, T., Liu, Q., Yang, Z., The SARS-CoV-2 outbreak: what we know. Int. J. Infect. Dis., 2020 Mar 11, 10.1016/j.ijid.2020.03.004.
255. Galeotti, C., Kaveri, S.V., Bayry, J., IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int. Immunol. 29 (2017), 491–498.
256. DesJardin, J.A., Snydman, D.R., Antiviral immunotherapy: a review of current status. BioDrugs Clin. Immunother. Biopharm. Gene Theroy 9 (1998), 487–507.
257. Krause, I., Wu, R., Sherer, Y., Patanik, M., Peter, J.B., Shoenfeld, Y., In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations–a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus. Med. Oxf. Engl. 12 (2002), 133–139.
258. Buckley, R., Schiff, R., The use of intravenous immune globulin in immunodiciencies disease. N. Engl. J. Med., 110, 1991, 7.
259. Deener, A., Mehra, A., Bernstein, L., Shliozberg, J., Rubinstein, A., Intravenous gammaglobulin treatment in HIV-1 infection. Immunol. Allergy Clin. 28 (2008), 851–859.
260. Dickinson, B.I., Gora-Harper, M.L., McCraney, S.A., Gosland, M., Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Ann. Pharmacother. 30 (1996), 1452–1464.
261. Ljungman, P., Cordonnier, C., Einsele, H., Bender-Götze, C., Bosi, A., Dekker, A., et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 21 (1998), 473–476.
262. Sarmiento, E., Lanio, N., Gallego, A., Rodriguez-Molina, J., Navarro, J., Fernandez-Yañez, J., et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int. Immunopharm. 9 (2009), 649–652.
263. Wyde, P.R., Chetty, S.N., Jewell, A.M., Boivin, G., Piedra, P.A., Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antivir. Res. 60 (2003), 51–59.
264. Bonney, D., Razali, H., Turner, A., Will, A., Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br. J. Haematol. 145 (2009), 667–669.
265. Shachor-Meyouhas, Y., Ben-Barak, A., Kassis, I., Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. Pediatr. Blood Canc. 57 (2011), 350–351.
266. Park, U.J., Hyun, S.K., Kim, H.T., Cho, W.H., Han, S.Y., Successful treatment of disseminated adenovirus infection with ribavirin and intravenous immunoglobulin in an adult renal transplant recipient: a case report. Transplant. Proc. 47 (2015), 791–793.
267. Saquib, R., Melton, L.B., Chandrakantan, A., Rice, K.M., Spak, C.W., Saad, R.D., et al. Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl. Infect. Dis. 12 (2010), 77–83.
268. Ghosh, S., Champlin, R.E., Ueno, N.T., Anderlini, P., Rolston, K., Raad, I., et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 28 (2001), 271–275.
269. Huang, Y.C., Lin, T.Y., Lin, Y.J., Lien, R.I., Chou, Y.H., Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur. J. Pediatr. 160 (2001), 91–94.
270. Lu, Y.-C., Fan, H.-C., Wang, C.-C., Cheng, S.-.N., Concomitant use of acyclovir and intravenous immunoglobulin rescues an immunocompromised child with disseminated varicella caused multiple organ failure. J. Pediatr. Hematol. Oncol. 33 (2011), e350–351.
271. Masci, S., De Simone, C., Famularo, G., Gravante, M., Ciancarelli, M., Andreassi, M., et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol. Immunotoxicol. 17 (1995), 33–47.
272. Randhawa, P., Pastrana, D.V., Zeng, G., Huang, Y., Shapiro, R., Sood, P., et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am. J. Transplant. 15 (2015), 1014–1020.
273. Sener, A., House, A.A., Jevnikar, A.M., Boudville, N., McAlister, V.C., Muirhead, N., et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 81 (2006), 117–120.
274. Ben-Nathan, D., Lustig, S., Tam, G., Robinzon, S., Segal, S., Rager-Zisman, B., Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188 (2003), 5–12.
275. Takada, A., Kawaoka, Y., Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13 (2003), 387–398.
276. Fu, Y., Cheng, Y., Wu, Y., Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol. Sin., 2020, 10.1007/s12250-020-00207-4.
277. Peiris, J.S.M., Chu, C.M., Cheng, V.C.C., Chan, K.S., Hung, I.F.N., Poon, L.L.M., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet Londn. Engl. 361 (2003), 1767–1772.
278. Jaume, M., Yip, M.S., Cheung, C.Y., Leung, H.L., Li, P.H., Kien, F., et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J. Virol. 85 (2011), 10582–10597.
279. Wang, S.-.F., Tseng, S.-.P., Yen, C.-.H., Yang, J.-.Y., Tsao, C.-.H., Shen, C.-.W., et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun. 451 (2014), 208–214.
280. Stockman, L.J., Bellamy, R., Garner, P.S.A.R.S., Systematic review of treatment effects. PLoS Med., 3, 2006, e343.
281. Ghoreschi, K., Laurence, A., O'Shea, J.J., Janus kinases in immune cell signaling. Immunol. Rev. 228 (2009), 273–287.
282. Yamaoka, K., Saharinen, P., Pesu, M., Holt, V.E. 3rd, Silvennoinen, O., O'Shea, J.J., The janus kinases (jaks). Genome Biol., 5, 2004, 253.
283. Zhang, S., Carriere, J., Lin, X., Xie, N., Feng, P., Interplay between cellular metabolism and cytokine responses during viral infection. Viruses, 10, 2018, 10.
284. Schoggins, J.W., Rice, C.M., Interferon-stimulated genes and their anti-viral effector functions. Curr. Opin. Virol. 1:6 (2011), 519–525.
285. Igaz, P., Tóth, S., Falus, A., Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm. Res. 50 (2001), 435–441.
286. Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., Sève, P., JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun. Rev., 18, 2019, 102390, 10.1016/j.autrev.
287. Fragoulis, G.E., McInnes, I.B., Siebert, S., JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 58 (2019), i43–i54.
288. Dhillon, S., Drugs. Tofacitinib: Rev. Rheumatoid Arthr. 77 (2017), 1987–2001.
289. Al-Salama, Z.T., Baricitinib, Scott L.J., A review in rheumatoid arthritis. Drugs 78 (2018), 761–772.
290. Genovese, M.C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.F., Meerwein, S., Pangan, A.L., Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391 (2018), 2513–2524.
291. Kuchipudi, S.V., The complex role of STAT3 in viral infections. J. Immunol. Res., 2015, 2015, 272359.
292. Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Stebbing, J., Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395 (2020), e30–e31.
293. Bechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A.P., Winthrop, K.L., Galloway, J.B., A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58 (2019), 1755–1766.
294. Chiu, Y.M., Chen, D.Y., Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expet Rev. Clin. Immunol. 16 (2020), 207–228.
295. Harigai, M., Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology 58 (2019), i34–i42.
296. Colombel, J.F., Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm. Bowel Dis. 24 (2018), 2173–2182.
297. Wu, D., Yang, X.O., TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect., 2020, 10.1016/j.jmii.2020.03.005.
298. Bergamini, A., Bolacchi, F., Bongiovanni, B., Cepparulo, M., Ventura, L., Capozzi, M., Sarrecchia, C., Rocchi, G., Granulocyte-macrophage colony-stimulating factor regulates cytokine production in cultured macrophages through CD14-dependent and -independent mechanisms. Immunology 101 (2000), 254–261.
299. Nicholls, J.M., Poon, L.L., Lee, K.C., Ng, W.F., Lai, S.T., Leung, C.Y., Chu, C.M., Hui, P.K., Mak, K.L., Lim, W., Yan, K.W., Chan, K.H., Tsang, N.C., Guan, Y., Yuen, K.Y., Peiris, J.S., Lancet 361 (2003), 1773–1778.
300. Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., Wei, H., Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev., 2020, 10.1093/nsr/nwaa041 Mar 13.
301. Burg, J., Krump-Konvalinkova, V., Bittinger, F., Kirkpatrick, C.J., GM-CSF expression by human lung microvascular endothelial cells: in vitro and in vivo findings. Am. J. Physiol. Lung Cell Mol. Physiol. 283 (2002), L460–L467.
302. Sterner, R.M., Sakemura, R., Cox, M.J., Yang, N., Khadka, R.H., Forsman, C.L., Hansen, M.J., Jin, F., Ayasoufi, K., Hefazi, M., Schick, K.J., Walters, D.K., Ahmed, O., Chappell, D., Sahmoud, T., Durrant, C., Nevala, W.K., Patnaik, M.M., Pease, L.R., Hedin, K.E., Kay, N.E., Johnson, A.J., Kenderian, S.S., GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133 (2019), 697–709.
303. Kerschbaumer, A., Sepriano, A., Smolen, J.S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I.B., Bijlsma, J.W.J., Burmester, G.R., de Wit, M., Falzon, L., Landewé, R., Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis., 2020, 10.1136/annrheumdis-2019-216656.
304. Crotti, C., Agape, E., Becciolini, A., Biggioggero, M., Favalli, E.G., Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects. Drugs 79 (2019), 1741–1755.
305. Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., H L H, Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395 (2020), 1033–1034.
306. Ferro, F., Elefante, E., Baldini, C., Bartoloni, E., Covid-19: the new challenge for rheumatologists. Clin. Exp. Rheumatol. 38 (2020), 175–180 Puxeddu I, talarico R, mosca M, bombardieri S.
307. Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., Galli, M., Covid-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. Clin. Exp. Rheumatol. 38 (2020), 337–3422020 Mar 22.